Capital International Investors
CRSP icon

Capital International Investors’s CRISPR Therapeutics CRSP Stock Holding History

Capital International Investors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.2M Buy
1,268,407
+81,613
+7% +$4.3M 0.01% 322
2026
Q1 		$56.5M Sell
1,186,794
-4,705,951
-80% -$248M 0.01% 317
2025
Q4 		$309M Buy
5,892,745
+243,487
+4% +$14.6M 0.05% 208
2025
Q3 		$366M Buy
5,649,258
+55,511
+1% +$3.19M 0.06% 187
2025
Q2 		$272M Sell
5,593,747
-479,371
-8% -$18.6M 0.05% 205
2025
Q1 		$207M Sell
6,073,118
-2,670,405
-31% -$113M 0.04% 218
2024
Q4 		$344M Buy
8,743,523
+816,789
+10% +$38.6M 0.06% 188
2024
Q3 		$372M Buy
7,926,734
+61,481
+0.8% +$3.12M 0.07% 182
2024
Q2 		$425M Buy
7,865,253
+28,179
+0.4% +$1.63M 0.09% 169
2024
Q1 		$534M Buy
7,837,074
+1,702,624
+28% +$122M 0.11% 158
2023
Q4 		$384M Buy
6,134,450
+48,938
+0.8% +$2.71M 0.09% 178
2023
Q3 		$276M Buy
6,085,512
+15,789
+0.3% +$815K 0.07% 197
2023
Q2 		$341M Buy
6,069,723
+46,085
+0.8% +$2.62M 0.08% 190
2023
Q1 		$272M Buy
6,023,638
+669,088
+12% +$32.5M 0.07% 211
2022
Q4 		$218M Buy
5,354,550
+12,132
+0.2% +$644K 0.06% 229
2022
Q3 		$349M Buy
5,342,418
+678,464
+15% +$49.2M 0.1% 185
2022
Q2 		$283M Buy
4,663,954
+1,061,802
+29% +$62.4M 0.08% 211
2022
Q1 		$226M Buy
3,602,152
+10,992
+0.3% +$690K 0.05% 249
2021
Q4 		$272M Sell
3,591,160
-586,507
-14% -$51.2M 0.06% 237
2021
Q3 		$468M Sell
4,177,667
-413,254
-9% -$51.9M 0.11% 180
2021
Q2 		$743M Sell
4,590,921
-277,768
-6% -$33.8M 0.17% 131
2021
Q1 		$593M Sell
4,868,689
-2,558,027
-34% -$386M 0.15% 147
2020
Q4 		$1.14B Buy
7,426,716
+32,442
+0.4% +$3.83M 0.31% 91
2020
Q3 		$618M Buy
7,394,274
+6,841,159
+1,237% +$607M 0.19% 124
2020
Q2 		$40.6M Hold
553,115
– – 0.01% 318
2020
Q1 		$23.5M Buy
553,115
+178,115
+47% +$9.2M 0.01% 310
2019
Q4 		$22.8M Buy
375,000
+237,000
+172% +$12.9M 0.01% 306
2019
Q3 		$5.66M Hold
138,000
– – ﹤0.01% 375
2019
Q2 		$6.5M Hold
138,000
– – ﹤0.01% 373
2019
Q1 		$4.93M Hold
138,000
– – ﹤0.01% 369
2018
Q4 		$3.94M Hold
138,000
– – ﹤0.01% 364
2018
Q3 		$6.12M Buy
+138,000
New +$7.23M ﹤0.01% 360

Other funds holding CRSP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors's CRSP Position: Q2 2026 in Review

Capital International Investors increased its CRISPR Therapeutics (CRSP) stake by 6.9% in Q2 2026, buying an estimated $4.3M and bringing the position to 1,268,407 shares worth $69.2M. The position accounts for 0.01% of the portfolio, ranked #322.

Capital International Investors first reported a position in CRSP in Q3 2018 and has held it in 32 quarters since. The position peaked at $1.14B in Q4 2020. 405 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Capital International Investors held 1,268,407 shares of CRISPR Therapeutics worth $69.2M as of Q2 2026.
  • Capital International Investors bought 81,613 CRISPR Therapeutics shares in Q2 2026, an estimated $4.3M.
  • CRISPR Therapeutics made up 0.01% of Capital International Investors's portfolio in Q2 2026, its #322 holding.
  • Capital International Investors first reported a position in CRISPR Therapeutics in Q3 2018 and has held it in 32 quarters since.
  • Capital International Investors's CRISPR Therapeutics position peaked at $1.14B in Q4 2020.
  • 405 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Capital International Investors's 13F filing for Q2 2026, filed 12 Aug 2026.